TY - JOUR
T1 - Activation of sphingosine kinase by lipopolysaccharide promotes prostate cancer cell invasion and metastasis via SphK1/S1PR4/matriptase
AU - Lee, Cheng-Fan
AU - Dang, Andrew
AU - Hernandez, Elizabeth
AU - Pong, Rey-Chen
AU - Chen, Benjamin
AU - Sonavane, Rajni
AU - Raj, Ganesh
AU - Kapur, Payal
AU - Lin, Hsin-Ying
AU - Wu, Shang-Ru
AU - Ko, Chun-Jung
AU - Lo, U-Ging
AU - Lee, Hsin-Yu
AU - Hsieh, Jer-Tsong
AU - Lee, Ming-Shyue
PY - 2019/7
Y1 - 2019/7
N2 - Gram-negative bacteria have been found to be a major population in prostatitis and prostate cancer (PCa) tissues. Lipopolysaccharide (LPS), a major compound of Gram-negative bacteria, with stimulatory activities in some cancer types, but has not been fully studied in PCa. In this study, we examined the effect of LPS on the invasion of PCa cells. Interestingly, LPS can enhance the invasiveness of PCa, but had no significant effect on PCa cell viability. Using protease inhibitor screening and biochemical analyses, matriptase, a member of the membrane-anchored serine protease family, is found to play a key role in LPS-induced PCa cell invasion. Mechanistically, Toll-like receptor 4 (TLR4, LPS receptor)-sphingosine kinase 1 (SphK1) signaling underlies LPS-induced matriptase activation and PCa cell invasion. Specifically, LPS induced the S225 phosphorylation of SphK1 and the translocation of SphK1 to plasma membrane, leading to the production of sphingosine 1-phosphate (S1P), ERK1/2 and matriptase activation via S1P receptor 4 (S1PR4). This phenomenon is further validated using the patient-derived explant (PDE) model. Indeed, there is a significant correlation among the elevated SphK1 levels, the Gleason grades of PCa specimens, and the poor survival of PCa patients. Taken together, this study demonstrates a potential impact of LPS on PCa progression. Our results provide not only a new finding of the role of bacterial infection in PCa progression but also potential therapeutic target(s) associated with PCa metastasis.
AB - Gram-negative bacteria have been found to be a major population in prostatitis and prostate cancer (PCa) tissues. Lipopolysaccharide (LPS), a major compound of Gram-negative bacteria, with stimulatory activities in some cancer types, but has not been fully studied in PCa. In this study, we examined the effect of LPS on the invasion of PCa cells. Interestingly, LPS can enhance the invasiveness of PCa, but had no significant effect on PCa cell viability. Using protease inhibitor screening and biochemical analyses, matriptase, a member of the membrane-anchored serine protease family, is found to play a key role in LPS-induced PCa cell invasion. Mechanistically, Toll-like receptor 4 (TLR4, LPS receptor)-sphingosine kinase 1 (SphK1) signaling underlies LPS-induced matriptase activation and PCa cell invasion. Specifically, LPS induced the S225 phosphorylation of SphK1 and the translocation of SphK1 to plasma membrane, leading to the production of sphingosine 1-phosphate (S1P), ERK1/2 and matriptase activation via S1P receptor 4 (S1PR4). This phenomenon is further validated using the patient-derived explant (PDE) model. Indeed, there is a significant correlation among the elevated SphK1 levels, the Gleason grades of PCa specimens, and the poor survival of PCa patients. Taken together, this study demonstrates a potential impact of LPS on PCa progression. Our results provide not only a new finding of the role of bacterial infection in PCa progression but also potential therapeutic target(s) associated with PCa metastasis.
KW - Adaptor Proteins, Signal Transducing/metabolism
KW - Disease Progression
KW - Enzyme Activation
KW - Humans
KW - Male
KW - Neoplasm Invasiveness
KW - Neoplasm Metastasis
KW - Phosphotransferases (Alcohol Group Acceptor)/metabolism
KW - Polysaccharides/pharmacology
KW - Prostatic Neoplasms/enzymology
KW - Serine Endopeptidases/metabolism
KW - Sphingosine-1-Phosphate Receptors/metabolism
U2 - 10.1038/s41388-019-0833-3
DO - 10.1038/s41388-019-0833-3
M3 - Article
C2 - 31152147
SN - 0950-9232
VL - 38
SP - 5580
EP - 5598
JO - Oncogene
JF - Oncogene
IS - 28
ER -